About 6,387 Worth Of Sarepta Therapeutics Inc. (SRPT) Shares Belongs To Its Director


As of Friday close, Sarepta Therapeutics Inc.’s (NASDAQ:SRPT) stock was down -$26.98, moving down -18.03 percent to $122.69. The average number of shares traded per day over the past five days has been 2,559,580 shares. 2 times new highs have been achieved over the past 5 days, with a -$21.23 fall in that time frame. In the last twenty days, the average volume was 2,132,370, while in the previous 50 days, it was 1,435,460.

Since last month, SRPT stock retreated -1.63%. Shares of the company fell to $117.11 on 03/17/23, the lowest level in the past month. A 52-week high of $159.84 was reached on 03/06/23 after having rallying from a 52-week low of $61.28. Since the beginning of this year, SRPT’s stock price has dropped by -5.32% or -$6.89, and marked a new high 9 times. However, the stock has declined by -23.24% since its 52-week high.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


SRPT stock investors should be aware that Sarepta Therapeutics Inc. (SRPT) stock had its last reported insider trading activity 121 days ago on Nov 17. Mayo Stephen, the Director of the company, disposed of 858 shares for $109.92 on Nov 17. It resulted in a $94,311 divestment by the insider. Chambers Michael Andrew added 57,100 shares at an average price of $104.43 on Sep 14. The insider now owns 108,178 shares following the transaction. On Aug 19, Director Chambers Michael Andrew bought 46,170 shares at $108.28 apiece. The transaction was valued at $4,999,230.

Valuation Metrics

The stock’s beta is 0.98. Besides these, the trailing price-to-sales (P/S) ratio of 11.93, the price-to-book (PB) ratio of 28.01.

Financial Health

In the three months ended September 29, Sarepta Therapeutics Inc.’s quick ratio stood at 3.80, while its current ratio was 4.10, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 4.01, and the total debt-to-equity ratio was 4.01. On the profitability front, the trailing twelve-month gross margin is 85.00% percent. In the year ended September 29, operating margins totaled -71.20%. Based on annual data, SRPT earned $793.02 million in gross profit and brought in $933.01 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -35.10%. Return on equity (ROE) for the past 12 months was -117.30%.

In Sarepta Therapeutics Inc.’s quarter-end financial report for September 29, it reported total debt of $1.54 billion against cash and short-term investments of $1.02 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. SRPT’s revenue rose 22.04% to $230.27 million during the quarter, while net income inched up to $258.43 million. While analysts expected Sarepta Therapeutics Inc. to report -$1.43 quarterly earnings, the actual figure was -$2.94 per share, beating the consensus estimate by -105.60%. During the quarter, the company generated -$96.28 million in EBITDA. The liabilities of Sarepta Therapeutics Inc. were 2.74 billion at the end of its most recent quarter ended September 29, and its total debt was $1.6 billion. The value of shareholders’ equity is $87.98 million.

Technical Picture

This quick technical analysis looks at Sarepta Therapeutics Inc.’s (SRPT) price momentum. With a historical volatility rate of 98.52%, the RSI 9-day stood at 31.71% on 17 March.

With respect to its five-day moving average, the current Sarepta Therapeutics Inc. price is down by -14.75% percent or -$21.23. At present, SRPT shares trade +0.52% above its 20-day simple moving average and +8.86% percent above its 100-day simple moving average. However, the stock is currently trading approximately -1.83% below its SMA50 and +68.48% above its SMA200.

Stochastic coefficient K was 51.82% and Stochastic coefficient D was 61.55%, while ATR was 9.23. Given the Stochastic reading of 13.06% for the 14-day period, the RSI (14) reading has been calculated as 38.87%. As of today, the MACD Oscillator reading stands at -5.88, while the 14-day reading stands at -6.35.

Analyst Ratings

Morgan Stanley upgraded its rating on Sarepta Therapeutics Inc. (NASDAQ: SRPT) to an Overweight in a note to investors on March 01, 2023. The analysts firm previously had an Equal-weight rating on the stock.Sarepta Therapeutics Inc. (SRPT) has been rated Buy by analysts. According to 0 brokerage firms, SRPT is a sell, and 3 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 2 analysts rate Sarepta Therapeutics Inc. stock as buy, with 16 recommending it as overweight.

With a median target price of $164.50, the current consensus forecast for the stock is $125.00 – $206.00. Based on these forecasts, analysts predict Sarepta Therapeutics Inc. (SRPT) will achieve an average price target of $168.50.


Please enter your comment!
Please enter your name here